These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 34207359)
1. Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma. Roderburg C; Loosen SH; Bednarsch J; Alizai PH; Roeth AA; Schmitz SM; Vucur M; Luedde M; Paffenholz P; Tacke F; Trautwein C; Ulmer TF; Neumann UP; Luedde T Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207359 [TBL] [Abstract][Full Text] [Related]
2. Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. Kim H; Kim J; Byeon S; Jang KT; Hong JY; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Kim ST Oncology; 2021; 99(6):365-372. PubMed ID: 33730723 [TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses. Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649 [TBL] [Abstract][Full Text] [Related]
4. Prognostic roles of leptin-signaling proteins, PD-L1, and tumor-infiltrating lymphocytes in surgically-resected biliary tract cancers. Byeon SJ; Chang MS; Cho HJ; Park JH; Kim KH; Park JH; Choi IS; Kim W; Han DS; Ahn HS; Heo SC J Surg Oncol; 2023 Mar; 127(4):587-597. PubMed ID: 36367404 [TBL] [Abstract][Full Text] [Related]
8. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies. Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854 [TBL] [Abstract][Full Text] [Related]
9. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma. Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of preoperative inflammatory markers in resectable biliary tract cancer - Validation and comparison of the Glasgow Prognostic Score and Modified Glasgow Prognostic Score in a Western cohort. Jansson H; Cornillet M; Björkström NK; Sturesson C; Sparrelid E Eur J Surg Oncol; 2020 May; 46(5):804-810. PubMed ID: 31848078 [TBL] [Abstract][Full Text] [Related]
12. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies. Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949 [TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients. Kitano Y; Yamashita YI; Nakao Y; Itoyama R; Yusa T; Umezaki N; Tsukamoto M; Yamao T; Miyata T; Nakagawa S; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H Ann Surg Oncol; 2020 Feb; 27(2):599-607. PubMed ID: 31407173 [TBL] [Abstract][Full Text] [Related]
14. Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. Gani F; Nagarajan N; Kim Y; Zhu Q; Luan L; Bhaijjee F; Anders RA; Pawlik TM Ann Surg Oncol; 2016 Aug; 23(8):2610-7. PubMed ID: 27012989 [TBL] [Abstract][Full Text] [Related]
15. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis. Lei C; Peng X; Gong X; Fan Y; Wu S; Liu N; Li L; Huang J; Zheng G; Long Z Aging (Albany NY); 2019 Dec; 11(24):12568-12580. PubMed ID: 31881008 [TBL] [Abstract][Full Text] [Related]
16. Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis. Frega G; Cossio FP; Banales JM; Cardinale V; Macias RIR; Braconi C; Lamarca A Cells; 2023 Aug; 12(16):. PubMed ID: 37626908 [TBL] [Abstract][Full Text] [Related]
17. Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma. Dong Z; Liao B; Shen W; Sui C; Yang J Dig Dis Sci; 2020 Feb; 65(2):480-488. PubMed ID: 31410753 [TBL] [Abstract][Full Text] [Related]
18. Targeting PD-1/PD-L1 in biliary tract cancer: role and available data. Mahmood RD; Graham K; Gleeson J; Hubner RA; Valle JW; McNamara MG Immunotherapy; 2023 May; 15(7):517-530. PubMed ID: 37009698 [TBL] [Abstract][Full Text] [Related]
19. Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study. Shoda J; Matsuda A; Shida T; Yamamoto M; Nagino M; Tsuyuguchi T; Yasaka T; Tazuma S; Uchiyama K; Unno M; Ohkohchi N; Nakanuma Y; Kuno A; Narimatsu H J Gastroenterol; 2017 Feb; 52(2):218-228. PubMed ID: 27358229 [TBL] [Abstract][Full Text] [Related]
20. Elevated Serum Levels of CCL23 Are Associated with Poor Outcome after Resection of Biliary Tract Cancer. Roderburg C; Labuhn S; Bednarsch J; Lang SA; Schneider AT; Hammerich L; Vucur M; Ulmer TF; Neumann UP; Luedde T; Loosen SH Mediators Inflamm; 2022; 2022():6195004. PubMed ID: 36505756 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]